Table 6 Antiviral efficacy in patients with COVID-19
From: Associated risk factors with disease severity and antiviral drug therapy in patients with COVID-19
|  | Severe (n = 178) | Non-severe (n = 372) | ||
|---|---|---|---|---|
Ribavirin | 7/17 | 41.2% | 22/23 | 95.7% |
Oseltamivir | 34/53 | 64.2% | 49/49 | 100.0% |
Arbidol | 22/30 | 73.3% | 109/110 | 99.1% |
Lopinavir/ritonavir | 0/0 | – | 2/2 | 100% |
Ribavirin+Oseltamivir | 9/20 | 45.0% | 38/38 | 100% |
Ribavirin+Arbidol | 12/12 | 100% | 18/19 | 94.7% |
Arbidol+Oseltamivir | 15/17 | 88.2% | 14/16 | 87.5% |